secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-268840
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm Q3 revenue $36.0M, net loss $0.30/sh; FY guidance reaffirmed
-----------------------------------------------------------------------

- U.S. XPOVIO net product revenue $30.2M, down from $32.0M year-over-year due to PAP use and 340B discounts.
- Net loss of $34.5M ($0.30/sh) improved from $36.3M ($0.45/sh) in Q3 2022; cash $209.2M as of Sept 30, 2023.
- Full-year 2023 guidance held: total revenue $145-160M, XPOVIO net revenue $110-125M, non-GAAP opex $240-255M.
- NCCN elevated XVd to preferred category 1 for lenalidomide-refractory multiple myeloma after 1-3 prior lines.
- Entered clinical collaboration with BMS to evaluate mezigdomide + selinexor in R/R myeloma post T-cell therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523268840/0001193125-23-268840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523268840/d578470d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer